These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25224383)

  • 1. Management of gout in general practice--a systematic review.
    Jeyaruban A; Larkins S; Soden M
    Clin Rheumatol; 2015 Jan; 34(1):9-16. PubMed ID: 25224383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
    Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP; Gilliland WR
    Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study.
    Rees F; Jenkins W; Doherty M
    Ann Rheum Dis; 2013 Jun; 72(6):826-30. PubMed ID: 22679303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2016 updated EULAR evidence-based recommendations for the management of gout.
    Richette P; Doherty M; Pascual E; Barskova V; Becce F; Castañeda-Sanabria J; Coyfish M; Guillo S; Jansen TL; Janssens H; Lioté F; Mallen C; Nuki G; Perez-Ruiz F; Pimentao J; Punzi L; Pywell T; So A; Tausche AK; Uhlig T; Zavada J; Zhang W; Tubach F; Bardin T
    Ann Rheum Dis; 2017 Jan; 76(1):29-42. PubMed ID: 27457514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 12. Casebook consults: improving outcomes in gout (multimedia activity).
    Doghramji PP; Mandell BF; Pope RS
    Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
    Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
    J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum urate goal attainment and associated factors in Chinese gout patients.
    Guo G; Dong C; Yin R; Yang Y; Zhao R; Wang Y; Guo J; Zhou W; Lu G
    Psychol Health Med; 2020 Sep; 25(8):931-939. PubMed ID: 31870173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
    Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.